Liposomal antineoplastic drugs and uses thereof
View Patent ↗This invention relates to liposomal antineoplastic agents (e.g., camptothecin) compositions and methods of using such compositions for treating neoplasia and for inhibiting angiogenesis. The compositions and methods are useful for modulating the plasma circulation half-life of an active agent.
1. A method for modulating the plasma circulation half-life of vinorelbine in a subject, comprising:
(a) providing a liposomal formulation comprising:
a liposome having free vinorelbine in solution and precipitated vinorelbine encapsulated therein; and
(b) adding a liposome having no vinorelbine encapsulated therein to the liposomal formulation;
wherein the liposome having encapsulated vinorelbine and the liposome having no encapsulated vinorelbine comprise sphingomyelin and cholesterol at a ratio in the range of about 75/25 mol %/mol % sphingomyelinl/cholesterol to about 30/50 mol %/mol % sphingomyelinl/cholesterol, wherein the ratio of the vinorelbine to lipid is 0.2-0.3:1 (w/w), and wherein the precipitated vinorelbine in the liposome is at least 50% of the total vinorelbine in the formulation; and
administering the liposomal formulation to the subject, thereby modulating the plasma circulation half-life of vinorelbine in the subject.
2. The method of claim 1 , wherein the plasma circulation half-life of the vinorelbine is increased.
3. The method of claim 1 , wherein the plasma area under the curve (AUC) of the vinorelbine is increased.
4. The method of claim 1 , wherein the serum half-life of the liposome having encapsulated vinorelbine is prolonged.
5. The method of claim 1 , wherein the liposome having encapsulated vinorelbine comprises a component that enhances precipitation of the vinorelbine.
6. The method of claim 1 , wherein the ratio of liposomes having encapsulated vinorelbine to liposomes having no encapsulated vinorelbine is from 1:0.5 to 1:1000.
7. The method of claim 1 , wherein the liposome having encapsulated vinorelbine and the liposome having no encapsulated vinorelbine comprises sphingomyelin and cholesterol in a 55:45 molar ratio.
8. The method of claim 1 , wherein the liposome having encapsulated vinorelbine and the liposome having no encapsulated vinorelbine comprises sphingomyelin and cholesterol in a 50:50 molar ratio.
9. The method of claim 1 , wherein the ratio of the vinorelbine to lipid is about 0.3:1 (w/w).
10. A method for modulating the plasma circulation half-life of vinorelbine in a subject, comprising:
(a) providing a liposomal formulation comprising:
a liposome having free vinorelbine in solution and precipitated vinorelbine encapsulated therein; and
(b) adding a liposome having no vinorelbine encapsulated therein to the liposomal formulation;
wherein the liposome having encapsulated vinorelbine and the liposome having no encapsulated vinorelbine comprise sphingomyelin and cholesterol at a ratio of about 55/45 mol %/mol % sphingomyelinl/cholesterol, wherein the ratio of the vinorelbine to lipid is 0.3:1 (w/w), and wherein the precipitated vinorelbine in the liposome is at least 50% of the total vinorelbine in the formulation; and
administering the liposomal formulation to the subject, thereby modulating the plasma circulation half-life of vinorelbine in the subject.